I suggest investors take a look at an under-followed company called Athersys (NASDAQ:ATHX). After decades of debate on the ethics of stem cell research, the rhetoric has ebbed and focus has shifted from ethics to the promises of clinical development. Companies all over the globe are now treading into the promising world of stem cells. Investors need to rethink this investment arena, and Athersys is one of the companies they should seriously consider.
While the bulls have long fantasized about huge profits from a miracle stem cell drug, the bears have consistently used facts about stem cell toxicities and their nascent state in the FDA drug development process to explain their reticence to jump onto stem cells' commercial...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|